Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3114062 SC
LY3114062 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY3114062 (SC) | EXPERIMENTAL | LY3114062 given as a single subcutaneous (SC) dose, in escalating dose cohorts starting at 2 mg. |
| LY3114062 (IV) | EXPERIMENTAL | LY3114062 given once intravenous (IV). |
| Placebo | PLACEBO_COMPARATOR | Placebo (sodium chloride injection) given as a single SC dose. |
| Name | Type | Description |
|---|---|---|
| LY3114062 SC | DRUG | LY3114062 administered SC. |
| Placebo | DRUG | Placebo administered SC. |
| LY3114062 IV | DRUG | LY3114062 administered IV. |
Inclusion Criteria: * Signs or symptoms of an inflammatory arthritis for a duration of at least 8 weeks at screening. * Presence of at least 3 out of 66 swollen joints at screening and baseline, as determined by the swollen joint count assessment forms. Exclusion Criteria: * Synthetic disease-mod...
LY3114062 is being studied for the treatment of inflammatory arthritis. It is an investigational small molecule developed by Eli Lilly and Company and has been tested in a Phase 1 clinical trial in adults with this condition. It is not yet approved for any use.
LY3114062 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program evaluating the compound in inflammatory arthritis.
LY3114062 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound remains investigational and has not been approved by the FDA or any other regulatory agency for inflammatory arthritis or any other indication.
LY3114062 has been evaluated in one completed Phase 1 trial, NCT02144272, titled "Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis." The randomized, double-blind, placebo-controlled study enrolled 41 adults aged 18 years and older across sites in Bulgaria, Georgia, Moldova, and Romania.
Yes. LY3114062 SC is an alternative name for LY3114062, the small molecule being developed by Eli Lilly and Company for inflammatory arthritis. Both names refer to the same investigational compound.
The Phase 1 trial NCT02144272 was a randomized, double-blind, placebo-controlled study of LY3114062 in 41 adults with inflammatory arthritis. Participants were 18 years or older, and the study enrolled patients rather than healthy volunteers. It has been completed and was conducted in Bulgaria, Georgia, Moldova, and Romania.